Seraxis
Pankaj Dalal has extensive work experience in the field of biotechnology and pharmaceuticals. Pankaj is currently working as a Sr Director-CMC and Process Development at Seraxis. Prior to this, they worked at Revance Therapeutics, Inc. as a Principal Scientist, where they led late-stage process development for a drug substance adhering to safety standards and implemented risk-based and QbD approaches for microbial platform development. Before that, they held the role of Senior Scientist at Adello Biologics, LLC and Associate Director at AstraZeneca. Pankaj also worked as a Sr. Scientist at Boehringer Ingelheim and Staff Scientist at bioMérieux. Pankaj Dalal started their career at Cadila Pharmaceuticals Ltd as an Assistant General Manager in biotechnology, where they cloned and expressed Hepatitis B surface antigen in yeast. Pankaj has experience in various aspects of process development, including optimization, purification, downstream process development, and scale-down models.
Pankaj Dalal pursued their education in the field of Microbiology, starting with their M.Sc degree at Gujarat University from 1979 to 1981. Pankaj then continued their academic journey at Paris-Sud University (Paris XI) where they completed their Ph.D in Microbiology from 1985 to 1989.
This person is not in any teams
Seraxis
Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, their GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Their main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic andprovide a long term cure to patients that does not require the use of immuno-suppression.Their corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to their shareholders.